

DAFTAR PUSTAKA

- Anonim, 2021. *Peraturan Presiden Republik Indonesia nomor 67 tahun 2021 tentang Penanggulangan Tuberkulosis*. Diakses dari <https://tbindonesia.or.id/wp-content/uploads/2021/08/Perpres-Nomor-67-Tahun-2021.pdf> pada tanggal 1 Juni 2024.
- Anonim, 2022. *Keputusan Kepala Badan Pengawas Obat dan Makanan Republik Indonesia no 65 tahun 2022 tentang Daftar Obat Generik Tertentu Wajib Uji Bioekivalensi*. https://standarobat.pom.go.id/storage/standard/Kepka_BPOM_No_65_Tahun_2022.pdf. Dikases tanggal 1 Juni 2024.
- Aït Moussa, L., El Bouazzi, O., Serragui, S., Soussi Tanani, D., Soulaymani A., and Soulaymani. R., 2016. Rifampicin and isoniazid plasma concentrations in relation to adverse reactions in tuberculosis patients: a retrospective analysis. *Therapeutic Advances in Drug Safety* 7(6). pp : 239-247
- Buxton LO., 2017, Pharmacokinetics and Pharmacodynamics: The Dynamics of Drug Absorption, Distribution, Action, and Elimination in Laurence L. Brunton, LL, and Lazo, JS., *Goodman & Gilman's: The Pharmacological Basis of Therapeutics, Thirteenth Edition*.
- Diacon AH, Patientia RF, Venter A, van Helden PD, Smith PJ, McIlleron H, Maritz JS, Donald PR. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. *Antimicrob Agents Chemother* 2007;51: 2994–2996
- Dollery, C., (editor), 1999, *Therapeutic Drugs*. 2nd edition. Churchill Livingstone, Edinburg.
- Fu S, Liao L, Yang Y, Bai Y, Zeng Y, Wang H and Wen J , 2022. The pharmacokinetics profiles, pharmacological properties, and toxicological risks of dehydroevodiamine: A review. *Front. Pharmacol.* pp: 01-16.
- Ignatious E, and Dooley, K, 2023, Chapter 65 : Chemotherapy of tuberculosis and non tuberculosis mycobacteria including leprosy. Dalam Brunton, LL and Knolmann, BC (editors), *Goodman and Gilman The Pharmacological Basis of Therapeutics*. pp1267-1287
- IUATLD-WHO, 1999, Assuring bioavailability of fixed-dose combinations of anti tuberculosis medication. A joint statement of the IUATLD and WHO. *Int. J Tuberc Lung Dis*. No 3(11) S282-S283
- Jindani A, Aber VR, Edwards EA, Mitchison DA. 1980. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. *Am Rev Respir Dis* No 121. pp: 939–949.
- Jindani A, Dor 'e CJ, Mitchison DA., 2003, Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. *Am J Respir Crit Care Med* 2003;167:1348–1354.
- Kementerian Kesehatan Republik Indonesia (Kemkes), 2022, *Laporan Penanggulangan Tuberkulosis*. Jakarta.

- Ki MS, Jeong D, Kang H-Y, et al, 2023, Real-world impact of the fixed-dose combination on improving treatment outcomes of drug-susceptible tuberculosis: a comparative study using multiyear national tuberculosis patient data. *BMJ Open Respir Res* 2023;10:e001758. doi:10.1136/bmjresp-2023-00.
- Knowles SR, Uetrecht J, Shear NH.,2000, Idiosyncratic drug reactions: the reactive metabolite syndromes. *Lancet* 2000; 356:1587–1591.
- Sbarbaro J, Blomberg B, Chaulet P, 1999, Fixed dose combination formulations for tuberculosis treatment. *Int. J Tuberc Lung Dis*. No 3(11) S286-S288
- Pameswari1, P., Halim, A., Yustika1, L., 2016. Tingkat Kepatuhan Penggunaan Obat pada Pasien Tuberkulosis di Rumah Sakit Mayjen H. A. Thalib Kabupaten Kerinci. *Jurnal Sains Farmasi & Klinis* , 2(2), 116-121
- Peloquin CA. 2002. Therapeutic drug monitoring in the treatment of tuberculosis. *Drugs* 62:2169 –2183. <http://dx.doi.org/10.2165/00003495-200262150-00001>.
- Ruslami R, Nijland H, Aarnoutse R, Alisjahbana B, Soeroto AY, Ewalds S, and van Crevel R, 2006, Letters to the Editor Evaluation of High- versus Standard-Dose Rifampin in Indonesian Patients with Pulmonary Tuberculosis, *Antimicrobial Agents and Chemotherapy*, Feb. 2006, pp: 822–823
- Ruslami R, Nijland HM, Alisjahbana B, Parwati I, van Crevel R, Aarnoutse RE.,2007. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. *Antimicrob Agents Chemother* 2007;51:2546–2551.
- Soedarsono S, Jayanti RP, Mertaniasih NM, Kusmiati T, Permatasari A, Indrawanto DW, Charisma AN, Lius EE, Yuliwulandari R, Hoa PQ, Phat NK, Thu VTA, Anh NK, Ahn S, Long NP , Cho YS, Shin JG, 2023, Development of population pharmacokinetics model and Bayesian estimation of rifampicin exposure in Indonesian patients with tuberculosis, *Tuberculosis* 139 pp:1-8.
- Dizaji SP, Taala A, Masoumi M, Ebrahimzadeh N, Fateh A, Siadat SD, and Vaziri F, 2017. Sub-minimum inhibitory concentration of rifampicin: a potential risk factor for resuscitation of Mycobacterium tuberculosis. *Antimicrobial Resistance and Infection Control*. No 6, pp1-5.
- Stott, KE, Pertinez IH, Sturkenboom MGG, Boeree MJ, Aarnoutse R, Ramachandran G., Requena-Me´ndez. A., Peloquin C., Koegelenberg CFN, Alffenaar JWC, Ruslami R, Tostmann A, Swaminathan S, McIlleron, H, and Davies G., 2018. Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis. *J Antimicrob Chemother* . no 73: 2305–2313 doi:10.1093/jac/dky152 Advance Access publication 26 April 2018
- Suryawati, 1994, *Rifampicin pharmacokinetics in Indonesian subjects. The effect of doses, disease, nutritional states, ages, and interactions with other antituberculosis drugs*. Thesis, Gadjah Mada University.

- Suyanto, D., Ascobat, P., Louisa, M., Santoso, P., Soetikno, V., 2021. Hubungan Kadar Rifampisin Dan Isoniazid Darah Dengan Konversi Sputum Pasien TB Paru Di Akhir Fase Intensif. Thesis. Fakultas Kedokteran Universitas Indonesia.
- Tierney L M Jr, McPhee S J, Papadakis M A (editors), 2005, *Current Medical Diagnosis & Treatment*. 44th edition. Lange Medical Books. San Francisco.
- Urso R, Bardi P, and Giorgi G, 2002, A short introduction to pharmacokinetics. *European Review for Medical and Pharmacological Sciences* no 6. Pp 33-44
- USPDI, 2005, *Drug Information for Health Care Professional*. 25th edition. Thomson Micromedex, Massachusetts.
- WHO, 1999, *Establishing the bioequivalence of Rifampicin in fixed dose formulations containing isoniazide with or without pyrazinamide and/or ethambutol compared to the single drug reference preparations administered in loose combination*. Model protocol. WHO Communicable Disease Cluster. Geneva.
- WHO, 1999, *Marketing Authorization of Pharmaceutical Products With Special Reference to Multisource (Generic) Products: A Manual for Drug Regulatory Authorities*. Geneva, pp:104-123.
- WHO, 1999, *Fixed dose combination tablets for the treatment of tuberculosis*. Report of an informal meeting 27 April 1999. WHO-Communicable Disease Cluster. Geneva
- van Ingen J, Aarnoutse RE, Donald PR, Diacon AH, Dawson R, Plemper van Balen G, Gillespie SH, Boeree MJ. Why do we use 600 mg of rifampicin in tuberculosis treatment? *Clin Infect Dis* 2011;52:e194–199.